KALMSCapital

Fmr Dir. of Finance/IR (S&P 1000). Now managing KALMS Capital, a private, non-commercial prop trading account. Opinions are mine alone, not investment advice

[KALMSCapital @KalmsCapital]

to have these anomalies (likely a drop in chamber pressure per ISRO) at this stage but are confident they will identify the root cause and fix it. We look at these dips as opportunities to continue to add as we don't believe we will see these prices by this time next year (2/2)

[KALMSCapital @KalmsCapital]

We suspect a couple of reasons for the selloff today is Dr. Yao, ASTS's Chief Technology officer, form 144 filing late Friday on his intent to sell 55k shares of $ASTS as well as some added uncertainty with the ISRO setback over the weekend. It is unusual for ISRO (1/2)

[KALMSCapital @KalmsCapital]

@tradedollarnut $ZIM Our model forecasts approx $3.10 EPS in Q1 2025. We expect they will guide conservatively to the tune of full year adjusted EBITDA between $1.7b-2.2B

[KALMSCapital @KalmsCapital]

We trimmed our $ZIM position last quarter and shifted funds to product tankers. We’re eyeing increasing our exposure, pending government trade policy clarity. Our model conservatively forecasts Q4 EPS of ~$4.55. We expect they will guide very conservatively for Q1.

[KALMSCapital @KalmsCapital]

@jays13704 @ByronOnX Are you able to reference where the 6.6B came from, we pulled the data from the Jan 13 company update into our model where they indicated a 2B pipeline. 6.6B would be a material change to our forward price target

[KALMSCapital @KalmsCapital]

We opened up a position in $GRRR. It looks promising—strong 189% YoY revenue growth and a $2B contract pipeline. AI-driven security tech is hot, and with a new focus on protecting shareholder value, this has potential for significant upside in the next 12 months

[KALMSCapital @KalmsCapital]

enhances shareholder value and strengthens $VKTX positioning for potential strategic partnership or acquisition. We remain optimistic (even more so after last night news) about Viking's capacity to deliver significant returns as clinical milestones approach (2/2)

[KALMSCapital @KalmsCapital]

We were clearly early in entering $VKTX but our long-term thesis remains intact. We are positive on this $250m share repurchases as we believe it reflects strong confidence in VK2735 outcomes and VK2809 NASH prospects. This move mitigates future dilution, (1/2)

[KALMSCapital @KalmsCapital]

$ASTS nabs $43M Space Force deal via SDA! This is a major win validating their satellite-to-mobile tech, boosting military comms and fueling commercial rollout. Huge for ASTS growth and U.S. space edge.

[KALMSCapital @KalmsCapital]

@toiletkingcap @tradedollarnut @christankerfund @Edark94 Our predictive AI model uses reported information and then determines relationships with current publicly available data to determine EPS. It's a different approach than typical EPS modeling. We are currently only testing it with a few stocks, $ZIM being one of them.

[KALMSCapital @KalmsCapital]

The market is awakening to $MU's undervalued status, driven by strong, multi-year demand outlook for HBM. Over 21.2% gain YTD. Micron's strategic position in the AI memory sector is becoming increasingly clear.

[KALMSCapital @KalmsCapital]

$ZIM congrats to the longs who stuck by their convictions, even when the stock sold off to $16 a little over 2 months ago. Wall street really needs to revisit their models and see why they missed their EPS estimates so badly.

[KALMSCapital @KalmsCapital]

Our model predicts $ZIM will announce approx. $9 EPS tomorrow. Q4 is also shaping up to be better than expected, thus we think they will raise FY Adj. EBITDA 400m. The challenge is what has been priced in. We think the market will initially react positively to the raise.

[KALMSCapital @KalmsCapital]

$ZIM earnings slightly beat our model EPS estimate, but they raised the mid point FY EBITDA significantly more than our 400m projection. Based on their FY guidance, this would mean approx. $3.50-4.00 in 4Q and almost $17 EPS for the full year!

[KALMSCapital @KalmsCapital]

@shakaran87 $220m

[KALMSCapital @KalmsCapital]

$ZIM With the Drewry WCI up 7% this week, Q4 is shaping up to being very similar to Q2 24 as we estimate an EPS north of $3. Assuming ZIM hits our target of approx. $9 EPS for Q3, and sticks to their div. policy, we are looking at almost $6.50 in addition div payments this year.

[KALMSCapital @KalmsCapital]

$TGTX We opened a position this morning after earnings. We discovered this company only after a colleague with MS told us she was switching from Ocrevus to Briumvi. After our team did their research, we like the LT potential of this company and drug.

[KALMSCapital @KalmsCapital]

None of this assumes surcharges from likely strike port delays. Our opinion, the drop in premarket is most likely a sell the news event. And this is what makes markets. The street Q3 est. is 5.80 EPS for $ZIM so clearly they are using different assumptions than us (6/6)

[KALMSCapital @KalmsCapital]

$ZIM Responding to some questions in regard to how we get to our approx. $9 EPS with rates dropping so much, one needs to understand how shipping revenue is recognized. We can assume on average it takes about 2-3 weeks to deliver a TEU across all shipping lines (1/6)

[KALMSCapital @KalmsCapital]

With the slower decline in rates in Q3 vs historically declines we think $ZIM EBIT will be closer to 2.15B vs 1.85B on the top end of the guidance, thus getting an approx. $10 EPS for the second half of the year (5/6)